TFF Pharmaceuticals, Inc. Share Price

Stocks

0K30

US87241J2033

Biotechnology & Medical Research

Real-time 07:43:34 31/10/2024 pm IST 5-day change 1st Jan Change
2.180 EUR +21.79% Intraday chart for TFF Pharmaceuticals, Inc. -.--% -

Valuation : TFF Pharmaceuticals, Inc.

Market Cap 1.05Cr 90.44L 85.09L 77.65L 1.45Cr 100Cr 1.46Cr 10Cr 3.9Cr 51Cr 3.95Cr 3.86Cr 162.2Cr P/E 2022 *
-
P/E 2023 -0.61x
Enterprise Value 51.56L 44.33L 41.71L 38.06L 71.03L 49Cr 71.39L 4.94Cr 1.91Cr 25Cr 1.94Cr 1.89Cr 80Cr EV / Sales 2022 *
-
EV / Sales 2023 1,59,20,656x
Free-Float
97.4%
Yield 2022 *
-
Yield 2023 -
3 years 1.42
Extreme 1.42
8
5 years 1.42
Extreme 1.42
8
10 years 1.42
Extreme 1.42
8
Manager TitleAgeSince
Chief Executive Officer 65 14/11/2024
Chief Tech/Sci/R&D Officer - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 65 14/11/2024
Date Insider Type Main position Quantity % Market Cap. Importance
03/07/24 Free

Director

6,330 0.2043%
03/07/24 Free

Chief Financial Officer

20,368 0.6574%
03/07/24 Free

Chief Executive Officer

6,330 0.2043%
Change 5-day change 1-year change 3-year change Capi.($)
+21.79%-.--%-.--% - 1.13Cr
-2.82%-7.44%-5.00%+10.84% 4.8TCr
+0.91%+0.32%+412.68%+538.55% 4.44TCr
-1.36%-3.20%+34.68%+18.61% 4.27TCr
-0.80%-3.71%-0.79%+66.48% 4TCr
-1.72%-2.61%+13.09%+42.33% 3.28TCr
-2.22%-1.33% - - 1.77TCr
-1.56%-2.20%+19.44%+107.62% 1.65TCr
+0.11%-2.03%+11.48%+31.60% 1.44TCr
-1.10%-5.45%+75.28%+38.16% 1.34TCr
Average +1.11%+0.15%+62.32%+106.77% 2.7TCr
Weighted average by Cap. -1.20%-1.05%+85.16%+127.05%

Financials

2022 2023
Net sales 0.5 0.43 0.4 0.37 0.68 47 0.69 4.75 1.84 24.03 1.86 1.82 76.45 0.73 0.63 0.59 0.54 1.01 69.57 1.02 7.03 2.72 35.56 2.76 2.7 113.16
Net income -3.18Cr -2.73Cr -2.57Cr -2.35Cr -4.38Cr -301.19Cr -4.4Cr -30Cr -12Cr -153.95Cr -12Cr -12Cr -489.89Cr -2.12Cr -1.83Cr -1.72Cr -1.57Cr -2.93Cr -201.39Cr -2.94Cr -20Cr -7.88Cr -102.94Cr -7.98Cr -7.8Cr -327.57Cr
Net Debt -1.64Cr -1.41Cr -1.33Cr -1.21Cr -2.26Cr -155.68Cr -2.27Cr -16Cr -6.09Cr -80Cr -6.17Cr -6.03Cr -253.22Cr -53.63L -46.11L -43.38L -39.59L -73.88L -51Cr -74.26L -5.14Cr -1.99Cr -26Cr -2.01Cr -1.97Cr -83Cr
Logo TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
Employees
19

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 0K30 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!